Follow us

Subscribe to our Newsletters

Search News Archives

 


Subscibe to our YouTube channel

 

 

E-Newsletter Month  
Lab Bulletin Monthly Update August view archive
Microscopy & Image Analysis August view archive
Separation Science August view archive
Weekly Update August (3) view archive

new all Newsletter Banner

For further information or to sign up to receive any of our E-Newsletters click here


Protagen to Apply UNIarray® Platform for Biogen Idec

publication date: May 31, 2011
 | 
author/source: Protagen
protagenProtagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis announced today that they will be using the UNIarray® Platform to help discover biomarkers in relapsing remitting multiple sclerosis for Biogen Idec, Inc. Under the terms of the agreement, Protagen will apply its UNIarray® technology platform and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial for the purpose of finding predictive and response biomarkers associated with multiple sclerosis (MS) therapy.

"There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers," said Dr. Peter Schulz-Knappe, CSO of Protagen AG. "Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression."

"Pharmaceutical companies recognize more and more the importance of autoantibody signatures for drug development, and Protagen provides the right technology and unique expertise for collaborations in this area", said Dr. Stefan Müllner, CEO.

Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer and neurodegenerative disorders. The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.

About Protagen AG - www.protagen.de

Protagen AG is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.



Can't find what you are looking for?

Search by company, product or location

Company Name:

Location:

Product:



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have a product enquiry, please contact the supplier directly.


Lab Bulletin is published by newleaf marketing communications ltd


Exhibitions & Events
«  »
SMTWTFS
 123456
78910111213
14151617181920
21222324252627
282930